{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:06:32Z","timestamp":1771830392461,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Anti-IgLON5 disease is a rare autoimmune neurological disorder characterized by sleep disturbances, movement disorders, cognitive decline, bulbar symptoms, and respiratory dysfunction, with a complex interplay between autoimmunity and neurodegeneration. Recent studies have provided insights into its clinical manifestations, immunological mechanisms, and potential therapeutic approaches. However, there is limited research on the diagnosis of Anti-IgLON5 disease and the assessment of immunomodulatory treatment effects from a metabolic perspective by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET-CT). This case describes a 59-years-old male presented with 1-year history of recurrent insomnia, low mood, staring spells, dysphagia, and choking while drinking water. Initially misdiagnosed with a gastrointestinal disorder or mental illness. The diagnosis was confirmed by positive serum and cerebrospinal fluid (CSF) tests for anti-IgLON5 antibodies, and 18F-FDG PET-CT showed abnormal FDG uptake in the medulla oblongata and left temporal lobe. After treatment with immunoglobulin pH4, mycophenolate mofetil tablets and corticosteroids significantly improved his condition. Follow-up at 3 months showed normalized metabolism on 18F-FDG PET-CT and improved sleep architecture. This case emphasizes the significance of anti-IgLON5 encephalitis in the differential diagnosis of complex sleep disorders, while also providing new insights and experiences regarding the evaluation of immune-modulatory therapy in the treatment of anti-IgLON5 encephalitis through 18F-FDG PET-CT. Overall, anti-IgLON5 disease is a multi-systemic condition that requires further research to identify precise and effective therapeutic strategies. Our case highlights the potential utility of 18F-FDG PET-CT in elucidating disease mechanisms and guiding clinical management.<\/jats:p>","DOI":"10.3389\/fnins.2026.1720844","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:20Z","timestamp":1771828220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: PET\/CT assessment of immunomodulatory therapy in anti-IgLON5 encephalitis with sleep apnea"],"prefix":"10.3389","volume":"20","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chengdu Fifth People\u2019s Hospital, The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1212\/NXI.0000000000000577","article-title":"Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy.","volume":"6","author":"Brunetti","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jamaneurol.2019.3638","article-title":"Distinctive magnetic resonance imaging findings in IgLON5 antibody disease.","volume":"77","author":"Chen","year":"2020","journal-title":"JAMA Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1474-4422(14)70127-9","article-title":"Sleep disorder associated with antibodies to IgLON5: Parasomnia or agrypnia?","volume":"13","author":"Della Marca","year":"2014","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and characterization of movement disorders in Anti-IgLON5 disease.","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy.","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1212\/NXI.0000000000000393","article-title":"Understanding anti-IgLON5 disease.","volume":"4","author":"Graus","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease.","volume":"146","author":"Gr\u00fcter","year":"2023","journal-title":"Brain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(15)60445-7","article-title":"IgLON5 autoimmunity and abnormal behaviours during sleep.","volume":"385","author":"H\u00f6gl","year":"2015","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ana.25857","article-title":"Effects of IgLON5 antibodies on neuronal cytoskeleton: A link between autoimmunity and neurodegeneration.","volume":"88","author":"Landa","year":"2020","journal-title":"Ann. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e200234","DOI":"10.1212\/NXI.0000000000200234","article-title":"Phenotypic insights into Anti-IgLON5 disease in IgLON5-Deficient mice.","volume":"11","author":"Lee","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12974-022-02520-z","article-title":"Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice.","volume":"19","author":"Ni","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1212\/NXI.0000000000000485","article-title":"Subacute encephalitis with recovery in IgLON5 autoimmunity.","volume":"5","author":"Ramanan","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: A case series, characterisation of the antigen, and post-mortem study.","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e200126","DOI":"10.1212\/NXI.0000000000200126","article-title":"Anti-LGI1 encephalitis with co-occurring IgLON5 antibodies: Clinical features and human leukocyte antigen haplotypes.","volume":"10","author":"Schiff","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000005859","article-title":"IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation.","volume":"91","author":"Sch\u00f6berl","year":"2018","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1212\/NXI.0000000000001009","article-title":"Delayed benefit from aggressive immunotherapy in waxing and waning Anti-IgLON5 disease.","volume":"8","author":"Shambrook","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3233\/JAD-201105","article-title":"Hypothalamic-Bulbar MRI hyperintensity in Anti-IgLON5 disease with serum-restricted antibodies: A case report and systematic review of literature.","volume":"79","author":"Tagliapietra","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2325","DOI":"10.1212\/WNL.0000000000207870","article-title":"In Vivo measurement of tau depositions in Anti-IgLON5 disease using [18F]PI-2620 PET.","volume":"101","author":"Theis","year":"2023","journal-title":"Neurology"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1720844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:22Z","timestamp":1771828222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1720844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":20,"alternative-id":["10.3389\/fnins.2026.1720844"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1720844","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1720844"}}